LeonaBio Earnings Call Transcripts
Fiscal Year 2026
-
Lasofoxifene is advancing as a promising, well-tolerated oral therapy for ER-positive, ESR1-mutated metastatic breast cancer, showing strong efficacy in combination with abemaciclib and addressing key resistance mechanisms. The pivotal ELAINE 3 trial is over halfway enrolled, with top-line data expected in 2027.
-
Six proposals, including share issuances, an equity plan, and an increase in authorized shares, were presented and all approved by the required majority. No questions were raised by stockholders, and final results will be filed with the SEC.
Fiscal Year 2025
-
Announced acquisition of lasofoxifene rights, expanding the pipeline with a phase III breast cancer asset and advancing ALS candidate ATH-1105. Raised $90 million to fund key milestones, with both programs targeting pivotal data in 2027. Lasofoxifene offers strong clinical and commercial potential.
Fiscal Year 2024
-
LIFT-AD is a pivotal Phase II/III study of fosgonimeton in mild to moderate Alzheimer's, using the GST composite endpoint to measure both cognitive and functional outcomes. Interim analysis supports continued study, and the approach addresses a major unmet need for accessible, disease-modifying therapies. Results are expected to inform regulatory pathways and future development.
-
The team highlighted leadership changes, a unique neurodegeneration pipeline, and promising clinical data for Fosgonimeton in Alzheimer's, with a pivotal LIFT-AD trial readout expected in the fall. Financial runway is strong, and expansion into ALS and other indications is planned.
-
A late-stage neurodegeneration pipeline is advancing, with the LIFT Alzheimer's trial nearing data readout and strong interim efficacy signals. Regulatory alignment is in place, and an ALS program is progressing to clinical trials. Cash reserves support near-term milestones.